FDA regulatory process manages stigma as Sprout and BAYER engage in pharma marketing.

The entities involved

• FDA →
  • The FDA approved Miplyffa for the treatment of Niemann-Pick disease.Sat 00:55
  • iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50
• Sprout →

  Japanese company

  Nothing else this week.

• BAYER →

  company in Prague, Czechia

  • Dr. Andrea Maier-Richter was appointed Head of Coatings & Adhesives at Bayer AG, succeeding Thomas Römer.Fri 13:20
  • ECB rate rise odds increase due to inflation, while Bayer raises profit forecast and geopolitical tensions persist.Tue 23:52

Related events

• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• FDA approval is the goal for product candidates from Daré Bioscience, Inc.Jun 7
• FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.Mon 14:49
• FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.Oct 22